Cassava Sciences (SAVA) Competitors $3.98 +0.56 (+16.37%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$3.96 -0.02 (-0.38%) As of 10/8/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAVA vs. GHRS, MGTX, SNDL, ERAS, KROS, ESPR, MNPR, CMPS, SVRA, and ZVRAShould you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include GH Research (GHRS), MeiraGTx (MGTX), SNDL (SNDL), Erasca (ERAS), Keros Therapeutics (KROS), Esperion Therapeutics (ESPR), Monopar Therapeutics (MNPR), COMPASS Pathways (CMPS), Savara (SVRA), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry. Cassava Sciences vs. Its Competitors GH Research MeiraGTx SNDL Erasca Keros Therapeutics Esperion Therapeutics Monopar Therapeutics COMPASS Pathways Savara Zevra Therapeutics GH Research (NASDAQ:GHRS) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability. Does the media refer more to GHRS or SAVA? In the previous week, Cassava Sciences had 6 more articles in the media than GH Research. MarketBeat recorded 6 mentions for Cassava Sciences and 0 mentions for GH Research. Cassava Sciences' average media sentiment score of 0.96 beat GH Research's score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the news media. Company Overall Sentiment GH Research Neutral Cassava Sciences Positive Do analysts recommend GHRS or SAVA? GH Research currently has a consensus target price of $32.00, suggesting a potential upside of 142.98%. Cassava Sciences has a consensus target price of $2.00, suggesting a potential downside of 49.75%. Given GH Research's stronger consensus rating and higher possible upside, equities research analysts plainly believe GH Research is more favorable than Cassava Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GH Research 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67Cassava Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Which has preferable earnings and valuation, GHRS or SAVA? GH Research is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGH ResearchN/AN/A-$38.96M-$0.74-17.80Cassava SciencesN/AN/A-$24.34M-$2.55-1.56 Do insiders and institutionals hold more shares of GHRS or SAVA? 56.9% of GH Research shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 41.6% of GH Research shares are held by insiders. Comparatively, 2.4% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is GHRS or SAVA more profitable? GH Research's return on equity of -16.71% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets GH ResearchN/A -16.71% -16.06% Cassava Sciences N/A -66.16%-53.11% Which has more volatility & risk, GHRS or SAVA? GH Research has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -0.98, suggesting that its stock price is 198% less volatile than the S&P 500. SummaryGH Research beats Cassava Sciences on 9 of the 13 factors compared between the two stocks. Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SAVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAVA vs. The Competition Export to ExcelMetricCassava SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$165.21M$2.64B$6.10B$10.55BDividend YieldN/A56.71%5.69%4.75%P/E Ratio-1.5623.6985.4727.60Price / SalesN/A729.21601.78232.87Price / CashN/A173.2337.9261.55Price / Book1.315.5313.136.76Net Income-$24.34M$32.78M$3.30B$275.88M7 Day Performance16.03%5.82%4.29%2.81%1 Month Performance82.57%13.16%9.45%9.24%1 Year Performance-84.08%1.69%86.64%35.42% Cassava Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAVACassava Sciences2.9345 of 5 stars$3.98+16.4%$2.00-49.7%-84.7%$165.21MN/A-1.5630Analyst ForecastGHRSGH Research2.5506 of 5 stars$13.06-0.3%$32.00+145.0%+104.5%$679.51MN/A-17.6510Analyst ForecastMGTXMeiraGTx4.0582 of 5 stars$8.41-0.5%$24.00+185.4%+99.0%$676.58M$33.28M-4.12300News CoverageAnalyst ForecastInsider TradeSNDLSNDL3.1072 of 5 stars$2.56-0.8%$4.50+75.8%+35.6%$672.72M$671.81M-9.482,516Analyst ForecastERASErasca2.6509 of 5 stars$2.33-3.7%$3.71+59.4%-3.6%$660.95MN/A-5.18120News CoverageAnalyst ForecastOptions VolumeKROSKeros Therapeutics2.8317 of 5 stars$15.62-2.0%$30.00+92.1%-73.3%$634.48M$3.55M50.39100Analyst ForecastESPREsperion Therapeutics3.8129 of 5 stars$3.12-5.5%$7.00+124.4%+24.2%$629.05M$332.31M-6.37200Analyst ForecastGap DownMNPRMonopar Therapeutics1.5775 of 5 stars$99.50+0.1%$97.33-2.2%+1,745.9%$613.92MN/A-29.8810Analyst ForecastHigh Trading VolumeCMPSCOMPASS Pathways3.164 of 5 stars$6.29-2.2%$16.29+158.9%+9.5%$603.46MN/A-3.42120Analyst ForecastSVRASavara2.7173 of 5 stars$3.46-0.9%$7.50+116.8%-8.2%$598.03MN/A-6.9220Trending NewsAnalyst ForecastZVRAZevra Therapeutics2.6642 of 5 stars$10.65+9.2%$24.00+125.4%+27.1%$597.78M$23.61M-50.7120High Trading Volume Related Companies and Tools Related Companies GH Research Competitors MeiraGTx Competitors SNDL Competitors Erasca Competitors Keros Therapeutics Competitors Esperion Therapeutics Competitors Monopar Therapeutics Competitors COMPASS Pathways Competitors Savara Competitors Zevra Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SAVA) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
